Creative Medical Tech (CELZ) Soars 68% on Positive StemSpine Data

Key points:
 Creative Medical Technology soars 68% on positive data from StemSpine two-year study 
 The study confirms the efficacy of the treatment in reducing chronic lower back pain 
 CEO exclaims the importance of bringing a non-surgical option to the market 

A leader in today’s top daily gainers, Creative Medical Technology (NASDAQ: CELZ) skyrocketed around 68% this morning after investors reacted well to the company announcing positive long-term data surrounding a leading chronic back pain treatment; StemSpine. CELZ stock reached gains of over 80% before consolidating slightly lower.

The company is known for working towards a regenerative approach to immunotherapy, urology, neurology, and orthopedics. A two-year study of StemSpine alludes to the significant efficacy of the treatment in reducing non-surgical chronic lower back pain.

Read Also: Best Healthcare Stocks To Buy Right Now

The treatment works by utilizing the patient’s own bone marrow aspirate for effective treatment of chronic lower back pain; a ground-breaking treatment in a critical area of medical treatment that is somewhat neglected. The study recorded no safety-related concerns over the two years, with the StemSpine procedure resulting in an impressive 87% efficacy rate in the concerned patients without any adverse effects. The long-term data is being prepared for peer review and eventually future orthopedic/sports medicine conferences.

X testing X

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Offering an attractive non-surgical option for patients is an important step forward in the management of chronic pain. Timothy Warbington, President, and CEO of Creative Medical stated:

“The positive two-year data from our StemSpine® pilot study are very encouraging, and we are excited to engage with practitioners on commercialization…We believe StemSpine® represents an attractive non-surgical option for many of the millions of Americans who suffer from non-surgical chronic lower back pain.”

As with a lot of medical companies that announce new, potentially ground-breaking treatments; Creative Medical Technology is at risk of unnerving volatility moving forward. Today’s 68% price rise is unlikely to hold as momentum slows and profit-takers step it.